Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 0143-9098

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 0143-9098). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Bortezomib For Injection 1)

Chemical structure of bortezomib, showing its molecular arrangement with labeled atoms and bonds representing the composition of the active ingredient bortezomib.*

FDA Label Image

Figure 1 (Bortezomib For Injection 2)

A Kaplan-Meier survival curve showing the percentage of patients over time in months. Two treatment groups are compared: Vc-MP (red line) and MP (blue line), with the Vc-MP group showing higher patient survival percentages throughout the 24-month period. The plot includes patient counts at risk at various time points and a log-rank test p-value indicating statistical significance.*

FDA Label Image

Figure 2 (Bortezomib For Injection 3)

A Kaplan-Meier survival curve showing the percentage of patients over time (months) comparing two treatments labeled Vc-MP (red dashed line) and MP (blue solid line). The graph includes a patient risk table below the x-axis and indicates a p-value less than 0.05 from a log-rank test.*

FDA Label Image

Figure 3 (Bortezomib For Injection 4)

A survival curve graph comparing the proportion of patients over time (days) treated with bortezomib versus dexamethasone. The vertical axis shows the proportion of patients, and the horizontal axis represents time in days up to approximately 450 days. The bortezomib group shows higher patient survival over time compared to dexamethasone, with corresponding patient counts listed at specific time points. Statistical significance is indicated with a p-value less than 0.0001 from a log-rank test.*

FDA Label Image

Figure 4 (Bortezomib For Injection 5)

A survival curve graph comparing the proportion of patients over time (days) treated with bortezomib versus dexamethasone. The y-axis represents the proportion of patients, and the x-axis shows time in days up to 450. Bortezomib shows a higher proportion of patients remaining over time compared to dexamethasone. Patient counts at multiple timepoints and a p-value from a log-rank test (<0.05) are included.*

FDA Label Image

Figure 5 (Bortezomib For Injection 6)

A survival curve chart comparing the percentage of patients over time (months) between two treatments: VcR-CAP and R-CHOP. The chart includes a log rank test p-value of less than 0.001 and shows subjects at risk for each group at multiple time points up to 60 months.*

FDA Label Image

Figure 6 (Bortezomib For Injection 7)

A Kaplan-Meier survival curve comparing the percentage of subjects alive over time in months from randomization for two groups, VcR-CAP and R-CHOP. The chart includes a hazard ratio with 95% confidence interval and a table showing the number of subjects at risk at various time points for each group.*

FDA Label Image

Hikma Vial Label (Bortezomib For Injection 8)

Label for Bortezomib for Injection, 3.5 mg per vial, lyophilized powder for intravenous or subcutaneous use. The label includes storage instructions, manufacturer Jiangsu Hansoh Pharmaceutical Group Co., Ltd., and distributor Hikma Pharmaceuticals USA Inc. It states Rx only, single-dose vial, cytotoxic agent, and discard unused portion instructions.*

FDA Label Image

Hikma Carton (Bortezomib For Injection 9)

Packaging label for Bortezomib for Injection 3.5 mg per vial, a lyophilized powder for solution by Hikma Pharmaceuticals USA Inc. The label indicates intravenous or subcutaneous use, single-dose vial, with reconstitution instructions and storage conditions. Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd., China.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.